Intra-Cellular Therapies Inc (NAS:ITCI)
$ 84.85 -1.15 (-1.34%) Market Cap: 9.00 Bil Enterprise Value: 8.13 Bil PE Ratio: 0 PB Ratio: 7.86 GF Score: 61/100

Intra-Cellular Therapies Inc to Feature Highlights of Several of its Development Programs Transcript

Oct 20, 2021 / 05:00PM GMT
Release Date Price: $41.54 (-0.67%)
Operator

Good afternoon, and welcome to Intra-Cellular Therapies Virtual Event, which will feature presentations on the company's pipeline, including lumateperone, ITI-1284, the PDE1 inhibitor platform and ITI-333. There will be 2 question-and-answer sessions during today's program. Questions can be submitted throughout the presentations. (Operator Instructions)

I will now turn this call over to Dr. Mates.

Sharon Mates
Intra-Cellular Therapies, Inc. - Co-Founder, Chairman, CEO & President

Thank you, operator. Good afternoon, everyone. I'm Dr. Sharon Mates, Chairman and CEO of Intra-Cellular Therapies. In today's virtual event, we will be sharing highlights of our development programs.

Joining me today from Intra-Cellular Therapies are Dr. Suresh Durgam, our Chief Medical Officer; and Dr. Robert Davis, our Chief Scientific Officer. They lead our clinical development and research efforts.

Dr. Durgam is a psychiatrist with nearly 25 years of clinical research experience in neuropsychiatric drug development. He has led clinical programs and

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot